axial spondyloarthritis

Showing 2 posts of 2 posts found.

novartis_outside_1

Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study

June 4, 2020
Research and Development Cosentyx, Novartis, axial spondyloarthritis

New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the …

novartis_outside_1

EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis

April 29, 2020
Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …

The Gateway to Local Adoption Series

Latest content